Hemoglobin E-beta-thalassemia syndrome

Hemoglobin E-beta-thalassemia (HbE/beta-thalassemia) is a compound heterozygous hemoglobin disorder that results from the co-inheritance of one hemoglobin E (HbE) allele and one beta-thalassemia allele. It is one of the most common severe forms of thalassemia worldwide, particularly prevalent in Southeast Asia, the Indian subcontinent, and parts of the Middle East. The condition primarily affects the hematologic system, leading to ineffective erythropoiesis and chronic hemolytic anemia of variable severity. The clinical spectrum is remarkably broad, ranging from a mild, transfusion-independent anemia to a severe, transfusion-dependent condition resembling beta-thalassemia major. Key clinical features include pallor, jaundice, hepatosplenomegaly, and failure to thrive in childhood. Patients with more severe forms may develop skeletal deformities due to bone marrow expansion, growth retardation, and iron overload — either from the disease process itself (increased intestinal iron absorption) or from chronic blood transfusions. Iron overload can lead to serious complications affecting the heart, liver, and endocrine organs, including cardiomyopathy, liver fibrosis, diabetes mellitus, and hypogonadism. Splenomegaly can be massive and may contribute to worsening anemia through hypersplenism. Management depends on disease severity. Mildly affected patients may require only folic acid supplementation and monitoring, while severely affected individuals need regular red blood cell transfusions combined with iron chelation therapy (such as deferasirox, deferoxamine, or deferiprone) to prevent iron overload complications. Splenectomy may be considered in cases of significant hypersplenism. Hematopoietic stem cell transplantation (HSCT) offers a potential cure for severely affected patients, particularly when a matched sibling donor is available. Hydroxyurea and fetal hemoglobin inducers have been investigated as potential therapies to reduce transfusion requirements. Luspatercept, a transforming growth factor-beta superfamily ligand trap, has also shown promise in reducing transfusion burden. Gene therapy approaches are under active investigation. Regular monitoring for complications of iron overload, including cardiac and endocrine assessments, is essential for long-term management.

Common questions about Hemoglobin E-beta-thalassemia syndrome